Johnson & Johnson (NYSE:JNJ) will release earnings for the fourth quarter before the opening bell on Wednesday, Jan. 21.
Analysts expect the company to report fourth-quarter earnings of $2.47 per share. That’s up from $2.04 per share in the year-ago period. The consensus estimate for Johnson & Johnson’s quarterly revenue is $24.16 billion (it reported $22.52 billion last year), according to Benzinga Pro.
As per the recent news, Johnson & Johnson, on Jan. 14, shared topline results from the investigational Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy for multiple myeloma, a type of blood cancer.
Shares of Johnson & Johnson fell 0.2% to close at $218.21 on Tuesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Bernstein analyst Lee Hambright maintained a Market Perform rating and raised the price target from $193 to $208 on Jan. 9, 2026. This analyst has an accuracy rate of 59%.
- Barclays analyst Matt Miksic maintained an Equal-Weight rating and raised the price target from $197 to $217 on Dec. 30, 2025. This analyst has an accuracy rate of 65%.
- Goldman Sachs analyst Asad Haider maintained a Buy rating and increased the price target from $213 to $240 on Dec. 19, 2025. This analyst has an accuracy rate of 68%.
- B of A Securities analyst Tim Anderson maintained the stock with a Neutral rating and raised the price target from $204 to $220 on Dec. 15, 2025. This analyst has an accuracy rate of 66%.
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $190 to $197 on Dec. 12, 2025. This analyst has an accuracy rate of 72%
Considering buying JNJ stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments